Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

By J. Olesen, H. Diener, I. Husstedt, P. Goadsby, D. Hall, Ulrich Meier, S. Pollentier, L. Lesko. New England Journal of Medicine, 2004

1,120 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Calcitonin gene-related peptide: physiology and pathophysiology. (2014, background): “However, the sensory fibers that CGRP is contained in are also associated with pain processes, and the development of CGRP antagonists has revealed the pivotal role that CGRP plays in migraine, and with it the therapeutic potential of CGRP receptor antagonists, which has led to a vibrant drug discov”
PATHOPHYSIOLOGY OF MIGRAINE (2006, background): “The recent development of nonpeptide highly specific CGRP antagonists, and the announcement of proof of concept for a CGRP antagonist in acute migraine (Olesen et al, 2004), firmly establish this as a novel and important new emerging principle for acute migraine.”
Pathophysiology of Migraine: A Disorder of Sensory Processing. (2017, methodology): “In a proof-of-principle phase II study using an Up/Down design rule, it was effective at a dose of 2 mg intravenously (638).”